PD-ECGF Biomarker for Renal Cell Carcinoma Diagnosis
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for diagnosing and prognosing renal cell carcinoma (RCC) lack effective biomarkers, leading to inadequate treatment responses and potential toxicity from therapies with unknown effectiveness.
Innovation Solution
The use of PD-ECGF as a biomarker for diagnosing cancer and predicting the response to anti-angiogenic therapies, determined through methods such as immunohistochemistry, ELISA, and western blotting, to assess PD-ECGF levels in tissue and plasma samples.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If current diagnostic methods are used for renal cell carcinoma, then existing biomarkers can be measured, but the diagnostic precision and treatment prediction capability are insufficient
Solution Approach 1:
The patent identifies and measures PD-ECGF protein levels as a new biomarker parameter, changing from traditional biomarkers to this specific parameter that provides both diagnostic precision and treatment prediction capability for renal cell carcinoma
Solution Approach 2:
The patent replaces traditional histology-based classification and existing biomarker systems with PD-ECGF protein measurement, substituting the old diagnostic mechanism with a more precise molecular marker system
2Ease of operation
If therapies are administered without reliable biomarker guidance, then treatment can be provided, but potential toxicity occurs with unknown effectiveness
Solution Approach 1:
The patent performs preliminary measurement of PD-ECGF protein levels before initiating anti-angiogenic therapy, enabling advance identification of patients who are likely to respond to treatment and those who may experience toxicity, allowing pre-treatment risk assessment
Solution Approach 2:
The patent establishes a feedback mechanism where PD-ECGF levels are measured to guide treatment decisions, creating a closed-loop system where biomarker information continuously informs therapy selection and monitoring to minimize toxicity
3Measurement precision
If PD-ECGF levels are measured in cancer patients, then diagnostic accuracy improves, but the complexity of the diagnostic process increases
Solution Approach 1:
The patent uses PD-ECGF protein as an intermediary biomarker that bridges the gap between traditional diagnostic methods and treatment prediction, serving as a measurable mediator that provides information about both disease presence and treatment response likelihood
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
PD-ECGF has been shown to be highly expressed in RCC and breast cancer tissues, and elevated plasma levels correlate with early progression in colorectal and RCC patients, indicating its potential as a novel biomarker for cancer detection, diagnosis, and prediction of treatment response.
Implementation Method 1
determining the levels of PD-ECGF in a sample from the subject
Data Source
AI summary
The present invention corresponds to the field of cancer and is related to predicting cancer detection, diagnosis, monitoring and prediction of response to treatment, in particular platelet derived-endothelial cell growth factor (PD-ECGF) levels for their use as a potential value in monitoring disease evolution and predicting response to anti-angiogenic treatment.